{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T21:45:57Z","timestamp":1770500757014,"version":"3.49.0"},"reference-count":18,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2000,10,1]],"date-time":"2000-10-01T00:00:00Z","timestamp":970358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2000,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The in vitro activities of the new triazole, ravuconazole (BMS-207147), were compared to those of fluconazole and itraconazole against 541 clinical isolates of\n            <jats:italic>Cryptococcus neoformans<\/jats:italic>\n            . Isolates were obtained from cerebrospinal fluid (396), blood (116), and miscellaneous clinical specimens (29). Overall, ravuconazole (MIC at which 90% of the isolates are inhibited [MIC\n            <jats:sub>90<\/jats:sub>\n            ], 0.25 \u03bcg\/ml) was more active than either itraconazole (MIC\n            <jats:sub>90<\/jats:sub>\n            , 0.5 \u03bcg\/ml) or fluconazole (MIC\n            <jats:sub>90<\/jats:sub>\n            , 8 \u03bcg\/ml). Among the isolates inhibited by \u226516 \u03bcg of fluconazole\/ml, 90.2% were inhibited by \u22641 \u03bcg of ravuconazole\/ml. On the basis of our findings and the favorable pharmacokinetic properties of ravuconazole, we suggest that ravuconazole may be useful for the treatment of infectious diseases due to\n            <jats:italic>C. neoformans<\/jats:italic>\n            and that further clinical studies to confirm these promising in vitro results are warranted.\n          <\/jats:p>","DOI":"10.1128\/aac.44.10.2883-2886.2000","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T10:06:42Z","timestamp":1027764402000},"page":"2883-2886","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":66,"title":["In Vitro Activities of Ravuconazole (BMS-207147) against 541 Clinical Isolates of\n            <i>Cryptococcus neoformans<\/i>"],"prefix":"10.1128","volume":"44","author":[{"given":"T.","family":"Yamazumi","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Medical Microbiology Division, Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa 52242"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A.","family":"Pfaller","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Medical Microbiology Division, Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa 52242"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. A.","family":"Messer","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Medical Microbiology Division, Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa 52242"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Houston","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Medical Microbiology Division, Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa 52242"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. J.","family":"Hollis","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Medical Microbiology Division, Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa 52242"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. N.","family":"Jones","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Medical Microbiology Division, Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa 52242"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm9707277"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/517056"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/174.4.812"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","unstructured":"Casadevall\n              A.\n              Perfect\n              J. R.\n          Cryptococcus neoformans\n          1998\n          351\n          380\n          American Society for Microbiology\n          Washington D.C.","DOI":"10.1128\/9781555818241"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.9.2236"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.2.313"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.epirev.a036195"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.10.2237"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.10.2243"},{"key":"e_1_3_2_11_2","unstructured":"Medical Economics Co. Inc\n          Physicians' desk reference\n          54th ed.\n          2000\n          1457\n          1460\n          Medical Economics Co. Inc.\n          Oradell N.J"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.8.4.515"},{"key":"e_1_3_2_13_2","unstructured":"National Committee for Clinical Laboratory Standards\n          Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A.\n          1997\n          National Committee for Clinical Laboratory Standards\n          Wayne Pa"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.2.471"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.1.169"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199503163321102"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/24.2.235"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.34.5.1280-1282.1996"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.46.623"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.44.10.2883-2886.2000","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.44.10.2883-2886.2000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:30:01Z","timestamp":1645461001000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.44.10.2883-2886.2000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,10]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2000,10]]}},"alternative-id":["10.1128\/AAC.44.10.2883-2886.2000"],"URL":"https:\/\/doi.org\/10.1128\/aac.44.10.2883-2886.2000","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,10]]},"assertion":[{"value":"2000-05-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-07-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-10-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}